Regeneron signs gene editing deal with Tessera for AATD
Market Access Pharma
December 1, 2025
Summary Regeneron Pharmaceuticals has announced a partnership with Tessera Therapeutics to develop a gene editing treatment for alpha-1 antitrypsin deficiency (AATD), a rare liver and lung disease. The deal involves